Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ribociclib plus endocrine maintenance after first-line chemotherapy in HR+/HER2- metastatic breast cancer
2017-003667-35Phase 2Completed
- Sponsor
- GBG Forschungs
- Start
- Nov 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of ribociclib in breast cancer, sponsored by GBG Forschungs. Primary endpoint: Progression-free survival. Started Nov 2017; status: completed.
02
Drugs
ribociclib
03
Conditions
breast cancer
Beyond the preview
Go deeper on 2017-003667-35.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-003667-35.